Vivos (RDGL) Net Cash Flow Growth (1y) (2011 - 2025)
Vivos (RDGL) Net Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -54.17% |
| 10 | Vivos | 22.64 Mn | 21.08 Mn | -3,105.00 | -154.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -154.34% |
| Sep 30, 2025 | 9.44% |
| Jun 30, 2025 | -270.96% |
| Mar 31, 2025 | 575.28% |
| Dec 31, 2024 | 1,693.53% |
| Sep 30, 2024 | -138.89% |
| Jun 30, 2024 | 212.49% |
| Mar 31, 2024 | 24.58% |
| Dec 31, 2023 | 119.68% |
| Sep 30, 2023 | 25.11% |
| Jun 30, 2023 | -83.70% |
| Mar 31, 2023 | 23.59% |
| Dec 31, 2022 | 25.97% |
| Sep 30, 2022 | -58.90% |
| Jun 30, 2022 | 50.71% |
| Mar 31, 2022 | -123.90% |
| Dec 31, 2021 | -142.81% |
| Sep 30, 2021 | 23.87% |
| Jun 30, 2021 | -242.37% |
| Mar 31, 2021 | 10,558.09% |